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Summary The purpose of this study was to determine the safety, efficacy and impact on quality of life of recombinant human erythropoietin
(r-HuEPO) for cancer patients undergoing radiotherapy (RT). An open-labelled randomized design was used, with patients randomized to
either treatment or control arms. Patients in the treatment arm received r-HuEPO given by subcutaneous injection at a dose of 200 units kg-'
day-' plus oral iron supplements (ferrous sulphate 325 mg p.o. t.i.d.). Entry was restricted to patients with carcinoma of the lung, uterine
cervix, prostate or breast who presented for RT with anaemia parameters reflective of 'the anaemia of chronic disease'. Radiotherapy policies
(portals, doses, fraction size, etc.) were determined by the site and stage of disease. Complete blood counts (CBCs) were obtained weekly.
The target level of haemoglobin was 15 g dl-1 for men and 14 g dl-1 for women. Quality of life (QOL) was assessed weekly by using an
analogue scale to judge energy, activities of daily living and overall quality of life. Forty-eight patients were entered in the study, 24 in the
treatment arm and 24 in the control arm. The prerandomization demographic characteristics and mean laboratory values were comparable in
both arms. The mean haemoglobin at completion was 13.6 g dl-1 for r-HuEPO-treated patients compared with 11.0 g dl-1 for control subjects
(P= 0.0012). Patients who received r-HuEPO demonstrated a mean weekly haemoglobin increase of 0.41 g dl-1 compared with a decrease
in mean haemoglobin level in controls for 6 of the 7 weeks of the study (mean weekly decrease of 0.073 g dl-'). Target levels of haemoglobin
were achieved by 41.6% of r-HuEPO-treated patients compared with none of the control subjects. The mean platelet count declined in both
arms of the study with RT but the decline from pretreatment was less rapid in r-HuEPO-treated patients (11.2% decrease) compared with
controls (26.3% decrease) and was statistically significant during weeks 4-6. Toxicity was minor with only mild irritation at the injection site.
Mean quality of life end points were superior in the treatment arm but not statistically significant. r-HuEPO had a beneficial effect on weekly
haemoglobin levels in patients undergoing RT with response rates similar to other studies. There was also a less rapid decline in weekly
platelet counts in r-HuEPO-treated patients compared with control subjects. Further studies are needed to address the optimum dose and
scheduling as well as the impact of r-HuEPO on clinical outcomes.
Keywords: erythropoietin; radiotherapy; anaemia in cancer
Anaemia is a common occurrence in cancerpatients at some point in
their disease course (Samuels and Bierman, 1956; Hirst, 1986;
Abels, 1992a; Leitgeh et al, 1994). The presence ofanaemia reflects
a reduction in red cell mass and a corresponding decrease in the
oxygen-carrying capacity of the blood (Bunn, 1991). Although the
severity is variable from patient to patient, anaemia can lead to
symptoms offatigue, dyspnoea and loss ofappetite and can cause or
aggravate cardiovascular and respiratory problems (Ludwig et al,
1993; Leitgeh et al, 1994). The causes ofanaemia in cancer patients
are often multifactorial including haemorrhage, haemolysis and iron
deficiency as well as tumour infiltration of bone marrow and the
toxicities of cancer therapy (radiation and chemotherapy) (Abels,
1992a,b; Spivak, 1992; Longo, 1993). One component may be
related to the so-called 'anaemia of chronic disease' (Lee, 1983;
Abels, 1992b; Longo, 1993). The anaemia ofchronic disease results
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from decreased erythrocyte lifespan (about 80 days rather than the
normal 120 days), impaired flow of iron from macrophages to
plasma and an inadequate erythropoetin response to anaemia (Miller
et al, 1990; Abels, 1992a,b; Kushner, 1992; Dshrsen and Hossfeld,
1994). In cancer patients erythropoietin production has been found
to be particularly depressed compared with patients with either iron
deficiency anaemia or other normochromic, normocytic anaemias
associated with chronic disease (Miller et al, 1990; Kettelhack et al,
1994). This may be partly related to the inhibitory effect of
increased cytokine production of tumour necrosis factor alpha and
interleukin 1 onerythropoesis (Dshrsen and Hossfeld, 1994; Spivak,
1994). Thus, the anaemia ofcancer is at least partially due to a defi-
ciency of erythropoietin (Miller et al, 1990; Abels, 1992a,b, 1993;
Spivak, 1992, 1994).
Erythropoietin is the primary regulatory factor in erythropoiesis
(Zanjani and Ascensao, 1989). It is an acidic glycoprotein with an
estimated molecular weight of 34 000 that is produced primarily in
the kidney (Jacobson et al, 1957; Wang et al, 1985; Spivak, 1989;
Zanjani and Ascensao, 1986). Tissue hypoxia induces erythro-
poietin production which stimulates erythroid progenitor cells
(G.oldberg et al, 1988; Zanjani and Ascensao, 1989; Spivak, 1992,
1994). Recently, through the use ofrecombinant technology exoge-
nous erythropoietin has become available. Thus, it is now possible
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Table 1 Demographic characteristics and prerandomization laboratory
valuesa
Demographic characteristics Control Treatment P-value
and laboratory datab arm arm
Age (years)
Sex
Male
Female
Diagnosis
Breast cancer
Lung cancer
Prostate cancer
Cervix cancer
Unknown
Previous transfusion
Yes
No
Haemoglobin (gm dl-1)
(men 14-18; women 12-16)
RBC count (x 106 mm-3)
(men 4.6-6.2; women 4.2-5.4)
WBC count (x 103 mm-3)
(4.8-10.8)
Platelets (x 103 mm-3)
(159-400)
Reticulocyte count (%)
(0.5-1.5)
Serum iron (gg dl-')
(men 80-160; women 60-135)
Serum ferritin (ng ml-')
(men 36-262; women 10-155)
Total iron-binding capacity
(TIBC) (,ug dl-') (250-350)
Serum folate level (ng ml-')
(2.5-17.5)
Serum B12 level (pg ml-')
(250-1000)
Serum erythropoetin level
(IU/I) (4-26)
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_r-HuEPO
.-I- ---- - -- Control
IS)9AL r,.
0 1 2 3 4 5 6 7
Week
Figure 1 (A) Haemoglobin; (B) platelets; (C) White blood cell count
to manipulate erythropoiesis independently of endogenous erythro-
poietin production (Spivak, 1994). Recombinant erythropoietin
(r-HuEPO) has previously been shown to increase the haematocrit
and reduce the transfusion requirement in patients with end-stage
renal disease undergoing haemodialysis (Esbach et al, 1989) and in
AIDS patients treated with zidovudine (Fischl et al, 1990). In addi-
tion, there are now a number of reports on the use of r-HuEPO to
correct anaemia in cancer patients (Platanias et al, 1991; Abels,
1992a,b, 1993; Miller et al, 1992; Case et al, 1993; Lavey and
Dempsey, 1993; Ludwig et al, 1993, 1994; Vijayakumar et al, 1993;
Dusenbery et al, 1994; Leitgeh et al, 1994; deCampos et al, 1995).
In the largest randomized trial published to date, Abels (1993)
demonstrated that r-HuEPO corrected anaemia and reduced transfu-
sion requirements compared with a control group forpatients with a
variety of cancers undergoing chemotherapy. However, this partic-
ular study excluded patients receiving radiotherapy (RT). In view of
the above, a prospective, randomized, open-labelled clinical trial
was conducted to determine the safety and efficacy of subcutaneous
r-HuEPO in cancer patients undergoing RT. A randomized design
was chosen to compare weekly changes in blood cell parameters
between the treatment and the control group in a prospective and
unbiased manner and to separate the toxicities associated with RT
from any unexpected toxicities of r-HuEPO administration in the
treatment arm. In addition, we sought to assess quality of life
measures between those patients in the treatment and control arms.
We have previously reported the interim analysis of the first 26
patients entered (Vijayakumar et al, 1993) and now present the final
report ofthe 48 patients who completed this study.
METHODS AND MATERIALS
The study was initiated in September 1991 and completed in
February 1996. The participating institutions were the departments
of radiation oncology at the University of Chicago (UC), the
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University of California in San Francisco (UCSF) and the Joint
Center for Radiation Therapy (JCRT) in Boston. Informed consent
was obtained from all patients before randomization. Entry was
restricted to patients with either carcinoma of the lung, uterine
cervix, prostate or breast who presented for radiation therapy with
anaemia. Patients were required to have a Karnofsky performance
status of . 70 and a life expectancy of at least 3 months. Only
patients who would undergo at least 4 weeks of RT were eligible.
Although not specifically considered an exclusion criteria, only
three patients in the r-HuEPO arm and two of the control patients
received concomitant chemotherapy. Thus, impact of r-HuEPO on
patients receiving RT cannot be considered confounded by the
addition of concomitant chemotherapy. Anaemia was considered
to be haemoglobin < 13 gm dl-' in males and < 12 gm dl-' in
female patients. So as to best approximate the anaemia of chronic
disease, patients with evidence of iron, folate or B deficiency or
guiaic-positive stool were excluded. Patients were required to have
serum iron of> 20%; ferritin > 20 ng ml-'; TIBC < 400 ,ug dl-' and
be direct Coomb's test negative. Metastatic disease was not an
exclusion criteria except for patients with lung primaries or
cerebral metastases.
Patients in the treatment arm received 200 units(U) kg-' of r-
HuEPO (Procrit, Ortho Biotech, Raritan, NJ, USA) subcutaneously,
five times a week, until the haemoglobin reached its target level.
Injections for up to 7 weeks were allowed considering this to be the
maximum length of a radical course of RT for the malignancies in
this study. The target levels of haemoglobin were 15 gm dl-' for
men and 14 gm dl-' for women. Once the target haemoglobin level
was achieved, the dose ofr-HuEPO was reduced by 50% for main-
tenance ofthis level until completion ofRT. All patients in the treat-
ment arm received iron (ferrous sulphate, 325 mg. p.o. t.i.d.)
supplements during the period of r-HuEPO administration. Iron
supplements were used to ensure adequate iron stores during
erythropoiesis in order to prevent the development of iron defi-
ciency anaemia (Van Wyck, 1989). Patients in the control arm did
not receive iron supplements. Radiotherapy treatment policies were
based on the site and stage ofthe disease and were at the discretion
of the treating physician in terms of total dose, fraction size, treat-
ment portals, etc. Complete blood counts (CBC) were obtained
prerandomization for baseline values (week 0) and weekly there-
after during the RT. The following parameters were analysed:
haemoglobin, total white blood cell count (WBC) and platelets.
A patient self-assessed, subjective quality of life assessment was
also obtained on all patients on a weekly basis. Patients were asked to
mark their assessment of quality of life in a visual analogue format.
Three aspects of quality of life were addressed: energy level, ability
to perform activities of daily living and overall quality of life. A
computer program was written for converting the subjective quality
oflife assessment to numerical objective values. At the completion of
RT blood counts were obtained on those patients available for
follow-up with a maximum follow up time of 18 months.
Patients were randomized between r-HuEPO and control by
creating random numbers seperately by disease site and treatment
centre in bins of 10 by a computer. The differences between the
control and treatment arm of the various CBC parameters were
analysed by subtracting the weekly parameter from the baseline
value for each patient. A mean of all patients' incremental/decre-
mental values for each parameter was calculated and the difference
between the control and treatment arm was tested. Statistical
analyses were carried out with the two-tailed t-test for two vari-
ables and the chi-square test for multiple variables.
Table 2 Mean changes in weekly haemoglobin levels for the treatment and
control armsa
Week studied Control r-HuEPO P-value
Baseline 10.72 12.07 0.220
Week 1 10.37 (16) 12.51 (16) 0.030
Week 2 10.39 (16) 13.02 (20) 0.001
Week 3 10.55 (19) 13.4 (22) 0.0004
Week 4 10.79 (16) 13.85 (23) 0.001
Week 5 10.67 (15) 14.38 (21) 0.000007
Week 6 10.63 (17) 14.38 (19) 0.0004
Week 7 10.52 (15) 14.69 (13) 0.00002
Table 3 Weekly mean change in haemoglobin level (g dl-1) subtracted from
the previous week's mean levela
Week studied Control r-HuEPO P-value
Week 1 -0.347 (16) 0.44 (16) 0.03
Week 2 -0.07 (15) 0.679 (16) 0.003
Week 3 -0.069 (16) 0.361 (19) 0.18
Week 4 0.309 (16) 0.525 (22) 0.32
Week 5 -0.169 (13) 0.433 (21) 0.015
Week6 -0.162(13) 0.21 (18) 0.17
Week 7 -0.029 (14) 0.1 (12) 0.73
aNumber in parentheses is sample size for that week.
Table 4 Mean changes in weekly platelet levels for the r-HuEPO and
control armsa
Week studied Control r-HuEPO P-value
baseline platelet level 351 295 0.11
Week 1 change 27.2 (15) -33.0 (16) 0.17
Week 2 change -2.1 (15) -23.4 (18) 0.57
Week 3 change -52.6 (18) -1.2 (20) 0.06
Week 4 change -82.2 (14) -7.9 (22) 0.03
Week 5 change -88.3 (14) -9.8 (18) 0.004
Week 6 change -106.8 (16) -49.3 (18) 0.05
Week 7 change -102.1 (15) -68.6 (13) 0.190
aNumber in parentheses is sample size for that week.
RESULTS
A total of48 patients were entered in the study. Halfofthe patients
were men and half women. There were 37 patients from UC, ten
patients from UCSF and one patient from the JCRT. The break-
down by cancer is as follows: lung cancer, 18 patients; breast
cancer, ten patients; prostate cancer, 16 patients; and uterine cervix
cancer, three patients. There was one patient whose primary diag-
nosis was unknown. There were six patients who were treated
palliatively, the remainder were treated with curative intent. Two
patients refused r-HuEPO injections after randomization; one
refused after 3 days of injections and the second before any drug
had been administered. These patients are excluded from the
analysis.
The demographic characteristics and prerandomization labora-
tory results are shown in Table 1. The only notable laboratory
value is the baseline mean haemoglobin level, which is greater by
more than 1 g in the treatment arm (12.0 g dl-') than in the control
arm (10.7 g dl-'). However, this difference is not statistically
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Table 5 Summary of the pre- and post-RT parameters for the r-HuEPO and
control arms
Control r-HuEPO P-value
Haemoglobin
Pre-RT 10.72 12.07 0.22
Post-RT 11.01 13.62 0.0012
Platelets
Pre-RT 351 295 0.11
Post-RT 258 262 0.92
WBC
Pre-RT 7.47 6.88 0.64
Post-RT 4.32 4.3 0.98
Table 6 Weekly mean quality of life scores for control and treatment arm
Week studied Control r-HuEPO P-value
Week 1 50.0 (15) 53.6 (17) 0.74
Week2 45.9 (15) 52.1 (17) 0.56
Week 3 53.6 (15) 57.6 (17) 0.73
Week 4 56.3 (15) 58.5 (17) 0.84
Week 5 56.9 (15) 64.6 (17) 0.47
Week 6 57.9 (15) 63.3 (17) 0.62
Week 7 56.3 (14) 72.7 (13) 0.15
Number in parentheses is sample size for that week.
significant (P = 0.22). In general, the two arms are well balanced
without significant differences in baseline characteristics. The
mean values represented by this table demonstrate a fairly classic
picture of the anaemia of chronic disease, specifically, the mean
iron and total iron binding capacity (TIBC) values are low-normal
and the reticulocyte count and ferritin levels are in the normal
range. The mean serum erythropoietin level for the entire group
was 26.7 IU ml'. The normal range in adults without anaemia is
4-26 IU per 1 (Mendenhall et al, 1984; Egrice et al, 1987). Thus,
the endogenous erythropoietin level similarly represents the
classic picture of the anaemia of malignancy with a value that is
elevated but below what would be expected for iron deficiency
anaemia (Mendenhall et al, 1984).
Figure 1A shows the treatment and control arms for the weekly
haemoglobin levels. The mean haemoglobin in the patients who
received r-HuEPO demonstrated a gradual increase from the base-
line level during the weeks of the study as shown by the upward
slope. The haemoglobin levels of patients in the control arm
demonstrated no significant change in mean haemoglobin during
this time period and have a static curve. The mean haemoglobin at
completion was 13.6 g dl-' for the treated patients compared with a
week 0 level of 12.0 g dl'. For the control patients, the completion
mean haemoglobin level was 11.0 g dl-I compared with a baseline
of 10.7 g dl-'. The differences between the r-HuEPO group and
control mean haemoglobin levels were statistically significant for
each week ofthe study. These data are also presented in Table 2.
These results might be considered misleading because the higher
baseline haemoglobin of the treated patients compared with the
control patients (12.0 g dl-' vs 10.7 g dl') inflates the difference in
the mean haemoglobin levels, especially during the later weeks of
the study. However, this baseline difference is eliminated when the
week-to-week changes in haemoglobin are analysed. This is
demonstrated in Table 3 where the weekly mean haemoglobin
100 200 300 400
Time (days)
500 600
Figure 2 Haemoglobin follow-ups
level of the treatment and control patients is subtracted from the
previous week's level during each of the 7 weeks of the study and
the differences between the two groups tested. For example, the
haemoglobin level obtained in week 1 is subtracted from the base-
line (week 0) haemoglobin, the haemoglobin from week 2 is
subtracted from week I, etc. This table shows that for each ofthe 7
weeks of the study there is an increase in haemoglobin from the
previous week for those patients who were treated with r-HuEPO.
The average net increase in haemoglobin per week is 0.41 g dl-'
and is greatest between weeks 0 and 5 before levelling off. The
maximum increase for 1 week is between weeks 1 and 2, when the
mean haemoglobin increases 0.68 g dl-'. Patients in the control arm
show a decrease in haemoglobin from the previous week's reading
for 6 of the 7 weeks of the study with a range of between 0.03 and
0.35 g dl-'.
The target level of haemoglobin of 15 g dl-' for men and
14 g dl' for women was achieved by 41.6% (10 out of 24) of the
patients in the r-HuEPO arm. This includes six men and four
women. The mean time to normalization of haemoglobin was 4.2
weeks for men and 3.9 weeks for women. None of the patients in
the control group reached these target haemoglobin levels. If the
target level of haemoglobin was considered to be 14 gm dl-' for
men and 13 g dl-' for women, as is the case in some laboratories,
then 65.2% of the r-HuEPO patients achieved this haemoglobin
level compared with only one control patient (5.2%). The type of
cancer did not have a predictive value on either the pre-RT haemo-
globin level or progression of haemoglobin during the RT for
either the r-HuEPO or the control group (data not shown).
Follow-up hemoglobin levels were obtained on a subset of
patients. The number of patients continually decreased as the
interval from the completion of RT increased because of patients
dying or being lost to follow-up. As demonstrated in Figure 2,
with a maximum interval of 18 months, the mean level of haemo-
globin in the r-HuEPO patients is consistently higher than in the
control patients. However, the small number of patients in which
follow-up haemoglobin levels were available preclude this differ-
ence from showing statistical significance.
Figure B and C show the changes in platelets and WBC
respectively. The mean platelet count in the control patients
demonstrated a progressive decline with RT from a week 0 level of
350 to an end of treatment level of 258, a 26.3% decrease. The
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mean platelet count in the r-HuEPO patients was 295 at the
commencement of RT and 262 at completion, only an 11.2%
decrease. A t-test for the differences between the pre- and post-RT
platelet values for the r-HuEPO and control groups indicates a
significantly different rate of decline (P = 0.03). This 'positive'
effect of r-HuEPO on platelets is shown in Figure lB as an initial
minimal increase in mean platelet count and then a levelling off
during weeks 3-5 with a more gradual decline during the final 2
weeks of RT. Table 4 demonstrates that the weekly changes in
mean platelet count for the r-HuEPO patients achieve borderline
significance during week 3 (P = 0.060) and are statistically signif-
icant during weeks 4-6 when compared with controls. Figure IC
demonstrates the lack of effect of r-HuEPO on the WBC values.
White blood cell counts decreased in both arms of the study with
RT. A comparison ofthe pre- and post-RT parameters for the treat-
ment and control arm are summarized in Table 5.
Adverse effects/quality of life
One patient in the treatment arm developed pruritis, which cleared
within 2 days, and he subsequently continued r-HuEPO adminis-
tration without further difficulties. Five other patients experienced
adverse effects during the trial that were considered unrelated to
r-HuEPO. Three patients developed herpes zoster in dermatomes
within the radiotherapy field (two were in the control arm and one
in the treatment arm). Two patients complained of dyspepsia,
attributed to iron supplements, although none discontinued taking
iron tablets. No increased skin or other side-effects were observed
during RT in the treatment arm.
A quality of life (QOL) survey was completed weekly during
RT by all patients. Three aspects of quality of life were addressed:
energy level, ability to perform activities of daily living and
overall quality of life. Our results demonstrate that the answers for
all patients were highly correlated for the three aspects meaning an
individual patient generally recorded a similar score for each ofthe
three questions. Thus, the results are presented as a single QOL
parameter. Table 6 shows the weekly mean QOL scores for the
treatment and control groups. Note that for each week of the study
there is a more favourable numerical assessment of QOL in the r-
HuEPO arm compared with the control arm. These weekly differ-
ences did not achieve statistical significance, however, because
there was a large variation in individual QOL scores in the control
arm. Nevertheless, as the table demonstrates, there is a strong trend
towards better QOL in patients who received r-HuEPO.
DISCUSSION
For cancer patients receiving RT, anaemia has been correlated with
unfavourable outcomes when compared with non-anaemic patients
for a number ofdisease sites (Dische, 1991). Most of the literature
concerns malignancies of the uterine cervix (Evens and Bergso,
1965; Hierlihy et al, 1969; Vigerio et al, 1973; Bush et al, 1978;
Dische et al, 1983; Mendenhall et al, 1984; Bush, 1986; Girinski et
al, 1989; Rader, 1990) and head and neck (Blitzer et al, 1984;
Overgard et al, 1989; Dubray et al, 1996). How anaemia is causally
related to poor outcome is not entirely clear but it is probably both
a marker of advanced tumour and indicative of some degree of
tissue hypoxia. Because it is an axiom in radiobiology that hypoxic
cells are less radioresponsive than aerated cells (Gray et al, 1953;
Palcic and Skarsgard, 1984), it has been standard treatment to trans-
fuse anaemic cancer patients to some arbitrary haemoglobin level
in an effort to improve tissue oxygenation as well as to enhance
patient comfort (Poskitt, 1987). Despite this practice, the routine
use of blood transfusion to improve serum haemoglobin level has
risks, including viral infection (HIV and hepatitis) and transfusion
reaction (Bove, 1987; Poskitt, 1987; Levine and Vijayakumar,
1993). In addition, there is the potential down-regulation of host
cellular immune function with transfusion (Blumberg and Heal,
1990). A number of retrospective reviews have documented
adverse outcomes (inferior overall and disease-free survival) in
patients receiving blood transfusions for a variety of malignancies
including colon/rectum, lung, prostate, uterine cervix, breast and
soft tissues (Rosenberg et al, 1985; Tartter et al, 1985; Arnoux et al,
1988; Blumberg et al, 1988; Corman et al, 1988; Heal et al, 1988;
Moores et al, 1989; Wobbes et al, 1989; Little et al, 1990;
McClinton et al, 1990; Casper et al, 1991). Thus, although transfu-
sion can improve tissue oxygenation and potentially enhance the
effectiveness ofRT, any radiobiological gain might be mitigated by
the adverse effects of transfusion on tumour immunosurveillance
(Levine and Vijayakumar, 1993). Recombinant erythropoetin offers
the possibility of correcting cancer-related anaemia without
subjecting patients to the risks oftransfusion.
The results of this study demonstrate the use of r-HuEPO in
improving the haemoglobin levels in anaemic cancer patients
undergoing RT with an average increase of about 0.4 g dl-' per
week during treatment. This improvement in haemoglobin was
seen in every week ofthe study and was greatest during the second
week with a mean increase of 0.68 g dl-'. Although the mean
haemoglobin level at completion was 13.6 g dl-', which is below
the targeted levels of 15 g dl-I for men and 14 g dl-' for women,
this represents an improvement over patients in the control arm
who showed no change with RT. Furthermore, when the target
levels are reduced to the more realistic values of 14 g dl-' for men
and 13 g dl-' for women, 65% of the r-HuEPO patients achieved
these values compared with only 5.2% of control patients.
These findings in our randomized study confirm the erythropoi-
etic effect of r-HuEPO demonstrated in previous non-randomized
studies of anaemic cancer patients undergoing RT as well as our
preliminary report (Lavey and Dempsey, 1993; Vijayakumar et al,
1993; Dusenbery et al, 1994). Lavey and Dempsey (1993)
described an improvement in mean haemoglobin level from
11.9 g dl-' to 15.1 g dl-' in 20 patients who received r-HuEPO
while undergoing RT for supradiaphragmatic tumours (Kushner,
1992). This is an approximate haemoglobin increase of 0.45 g dl-'
per week over a 7-week RT treatment course. Similarly,
Dusenbery et al (1994) showed an improvement in mean haemo-
globin from 10.3 to 13.2 g dl-' in 15 patients with uterine cervix
cancer who received r-HuEPO during RT, which is an increase
of 0.5 g dl' per week (Dusenbery et al, 1994). These studies
demonstrate an increase in mean haemoglobin that is slightly
greater than the average weekly haemoglobin increase in our study
of 0.41 g dl-'. This may be explained by the fact that patients in
each of these studies received r-HuEPO as early as 10 days before
the start of RT, whereas patients in our study started r-HuEPO
during the first week of RT.
Despite the favourable effect on mean haemoglobin levels seen
in these studies the optimum dose and scheduling of r-HuEPO for
cancer patients has not been established. Our study used 200 units
kg-' for 5 consecutive days as the initial dose and then decreased
the dose by 50% once the anaemia was corrected. This was similar
to the dose and scheduling of Dusenbery et al (1994) and reflects
the favourable results of patients with chemotherapy-induced
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anaemia reported by Platanias et al (1991) in a dose escalation
study of r-HuEPO that demonstrated the highest response rates in
patients who received either 200 or 300 U kg-' for 5 days rather
than lower dose levels. However, Lavey and Dempsey (1993) used
300 U kg-' three times only during the first week and then
150 U kg-' (three times a week) for the remainder of the RT. This
dosing schedule is fairly close to that used in the two largest expe-
riences of r-HuEPO in patients with cancer-related anaemia
(Abels, 1992a,b, 1993; Ludwig et al, 1993, 1994) including
patients receiving combination chemotherapy (Case et al, 1993).
Response rates in these studies are defined differently but are
approximately in the 40 to 50% range of patients tested, which is
similar to our results. Thus, the correct r-HuEPO dose for RT-
treated cancer patients is probably at least 150 U kg-' given three
times per week and preferably at least 1 week before the
commencement of RT. The dose can be reduced once the anaemia
is corrected for the remainder ofthe RT.
There were no adverse effects related to the r-HuEPO in our
patients, except for minor irritation at the injection site. This was
similar to the experience of Lavey and Dempsey (1993).
Dusenbery et al (1994) did describe deep venous thrombosis
(DVT) occurring in 4 of 15 patients either during orjust thereafter
r-HuEPO administration (Dusenberg et al, 1994). Platanias et al
(1991) also reported DVT occurring in two of the eight patients
treated at the highest dose level (300 U kg-') of r-HuEPO and
Miller et al (1990) had I patient out of 21 develop DVT, although
this was in the lowest dose group (25 U kg-'). In a placebo-
controlled trial by Case et al (1993) the only statistically signifi-
cant difference in the incidence of any adverse effect in
r-HuEPO-treated patients compared with controls was diarrhoea
and diaphoresis. Other reports have similarly shown the drug to be
fairly well tolerated at the dose levels used for cancer patients
(Abels, 1993; Ludwig et al, 1993; deCampos et al, 1995).
We compared quality of life end points between r-HuEPO-
treated and control patients and found that for each week of study
there was a more favourable QOL assessment in the treated
patients, although wide variation of responses in the control group
precluded statistical significance. Nevertheless, this trend toward
improved QOL in r-HuEPO-treated patients is reflected in the
literature with most (Abels, 1992b, 1993; Case et al, 1993; Ludwig
et al, 1993; Leitgeh et al, 1994) but not all (Dusenberg et al, 1994)
series showing a benefit in various quality of life parameters over
concurrent or historical controls.
One unexpected finding in our study was the positive effect ofr-
HuEPO on platelets. The gradual decline in platelets with partial
body irradiation has been previously reported (Yang et al, 1995).
Although the r-HuEPO-treated patients in this study demonstrated
a decline in mean platelet level with RT there was clearly seen a
less rapid decline than in the control group. This effect has also
been described by de Campos et al (1995), who noted fewer
platelet transfusions in patients with small-cell-lung cancer treated
chemotherapy and RT who received r-HuEPO compared with
patients who did not. This thrombopoietic effect of r-HuEPO and
its therapeutic implications has been discussed in detail by one of
us (SV) in a separate communication (Vijayakumar et al, 1998).
In summary, this study confirms the findings of our preliminary
report of the beneficial effect of r-HuEPO on haemoglobin levels
in patients undergoing RT for a variety ofmalignancies. The mean
haemoglobin increase in those patients who received r-HuEPO
was 0.41 g dl-' per week. By our stringent definition of response
(target haemoglobin level of 15 g dl-' for men and 14 g dl-' for
women), 41.6% ofpatients responded, which is equivalent to other
studies ofanaemic cancer patients. Further, r-HuEPO was found to
be safe at the dose levels used and had a favourable impact on
quality of life end points. Future studies need to address the
optimum dose and scheduling for RT patients and to prospectively
compare outcomes from treatment of patients receiving r-HuEPO
with control patients.
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